These findings suggest a model in which chronic metabolic dysfunction and c‐Fos activation converge to drive liver pathology across the MASLD‐HCC spectrum, identifying c‐Fos as a potential therapeutic target in metabolic liver disease and cancer. Here, FOS is linked to hepatocellular carcinoma.